Please use this identifier to cite or link to this item:
|Title:||Targeting mitochondrial apoptosis to overcome treatment resistance in cancer||Authors:||Ngoi N.Y.L.
|Issue Date:||1-Mar-2020||Publisher:||MDPI AG||Citation:||Ngoi N.Y.L., Choong C., Lee J., Bellot G., Wong A.L.A., Goh B.C., Pervaiz S. (2020-03-01). Targeting mitochondrial apoptosis to overcome treatment resistance in cancer. Cancers 12 (3) : 574-574. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers12030574||Abstract:||© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Deregulated cellular apoptosis is a hallmark of cancer and chemotherapy resistance. The B-cell lymphoma 2 (BCL-2) protein family members are sentinel molecules that regulate the mitochondrial apoptosis machinery and arbitrate cell fate through a delicate balance between pro-and anti-apoptotic factors. The recognition of the anti-apoptotic BCL2 gene as an oncogenic driver in hematological malignancies has directed attention toward unraveling the biological significance of each of the BCL-2 superfamily members in cancer progression and garnered interest in the targeting of apoptosis in cancer therapy. Accordingly, the approval of venetoclax (ABT-199), a small molecule BCL-2 inhibitor, in patients with chronic lymphocytic leukemia and acute myeloid leukemia has become the proverbial torchbearer for novel candidate drug approaches selectively targeting the BCL-2 superfamily. Despite the inspiring advances in this field, much remains to be learned regarding the optimal therapeutic context for BCL-2 targeting. Functional assays, such as through BH3 profiling, may facilitate prediction of treatment response, development of drug resistance and shed light on rational combinations of BCL-2 inhibitors with other branches of cancer therapy. This review summarizes the pathological roles of the BCL-2 family members in cancer, discusses the current landscape of their targeting in clinical practice, and highlights the potential for future therapeutic inroads in this important area.||Source Title:||Cancers||URI:||https://scholarbank.nus.edu.sg/handle/10635/169447||ISSN:||20726694||DOI:||10.3390/cancers12030574|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
|Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer.pdf||Published version||800.83 kB||Adobe PDF|
checked on Jun 25, 2022
checked on Jun 23, 2022
checked on Jun 23, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.